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Synergistic eﬀects of hyaluronate – epidermal
growth factor conjugate patch on chronic wound
healing
Yun Seop Kim,a Dong Kyung Sung,b Won Ho Kong,a Hyemin Kima and
Sei Kwang Hahn *a
The proteolytic microenvironment in the wound area reduces the stability and the half-life of growth
factors in vivo, making diﬃcult the topical delivery of growth factors. Here, epidermal growth factor (EGF)
was conjugated to hyaluronate (HA) to improve the long-term stability against enzymatic degradation and
the therapeutic eﬀect by enhancing the biological interaction with HA receptors on skin cells. After the
synthesis of HA–EGF conjugates, they were incorporated into a patch-type formulation for the facile
topical application and sustained release of EGF. According to ELISA, the HA–EGF conjugates showed a
long-term stability compared with native EGF. Furthermore, HA–EGF conjugates appeared to interact
with skin cells through two types of HA and EGF receptors, resulting in a synergistically improved healing
eﬀect. Taken together, we could conﬁrm the feasibility of HA–EGF conjugates for the transdermal treat-
ment of chronic wounds.
Introduction
Chronic wounds such as diabetic ulcers arise from tissue inju-
ries that heal slowly. Unlike acute wounds, the exudate from
chronic wounds contains relatively high levels of tissue-
destructive proteases and low levels of growth factors, resulting
in poor wound healing.1,2 The application of exogenous
growth factors may compensate for the lack of endogenous
growth stimulation. Growth factors influence and modulate
epidermal and dermal regeneration, angiogenesis, and granu-
lation formation, but all these processes are inhibited in
chronic wounds. The native growth factors are short-lived in
the highly proteolytic wound environment, requiring repeated
topical applications. The use of native growth factors makes
wound healing therapies expensive due to a large amount of
dose with questionable eﬃcacy in the proteolytic wound
environment of the skin.
The covalent conjugation of poly(ethylene glycol) (PEG) to
proteins (PEGylation) has become a popular method to
increase stability, decrease immunogenicity and antigenicity,
and increase the half-life of proteins in vivo. Other polymers
for the protein conjugation have been developed with the aim
of improving the biological function and providing a better
stability.3,4 For example, Keefe et al. demonstrated that the
covalent conjugation of poly(carboxybetaine) to
α-chymotrypsin improved the enzyme stability retaining its
native binding aﬃnity.5 A dextrin–recombinant human epider-
mal growth factor (rhEGF) conjugate was synthesized for
masking rhEGF bioactivity and preventing the proteolysis by
neutrophil elastase.6–8 The conjugation of growth factors to
heparin can also extend their half-lives and enhance their
binding aﬃnity to cell surface receptors for intracellular sig-
naling, thereby increasing the bioactivity.9,10 Furthermore,
another research group developed a heparin-mimicking
polymer that stabilizes fibroblast growth factors and activates
fibroblast growth factor receptors.11–13 We previously reported
the conjugation of hyaluronate (HA) with human growth hor-
mones (hGH) for eﬀective transdermal delivery.14
Among various biomacromolecules, HA is well known for
remarkable characteristics such as hygroscopic, rheological,
biocompatible, immunocompatible, and viscoelastic pro-
perties. In addition, HA facilitates regeneration and wound
healing by regulating cell functions via binding to receptors
such as cluster determinant 44 (CD44) and receptor for HA
mediated motility (RHAMM) expressed on the surface of skin
cells including fibroblasts and keratinocytes.15 In addition,
epidermal growth factor (EGF), a single polypeptide chain of
53 amino acids with three interchain disulfide bonds, plays an
important role in wound healing owing to its positive eﬀect on
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collagen deposition and proliferation, and migration of kerati-
nocytes, fibroblasts and vascular endothelial cells at the
wound area.16
In this work, we developed HA–EGF conjugates to protect
from proteolytic degradation by trypsin and improve the bio-
logical interaction with skin cells of keratinocytes for facili-
tated chronic wound healing. The synthesized HA–EGF conju-
gate was characterized by gel permeation chromatography
(GPC), circular dichroism (CD) spectroscopy, enzyme-linked
immunosorbent assay (ELISA), and Bradford assay. The syner-
gistic eﬀect of HA–EGF conjugates on keratinocytes was
assessed by confocal microscopy, flow cytometric analysis, pro-
liferation assay, and ELISA. After that, we incorporated the con-
jugates into highly concentrated HA patches for long-term sus-
tained release of the conjugates in vivo. The prepared patch-
type HA–EGF conjugates were applied for the long-term reten-
tion of EGF on the wound area and thereby improved the
therapeutic eﬀect in diabetic wound model rats.
Experimental
Materials
Sodium hyaluronate (HA) was purchased from Lifecore
Biomedical (Chaska, MN). Recombinant human EGF was
obtained from Genscript (Piscataway, NJ). Sodium periodate,
sodium cyanoborohydride, ethyl carbazate, tert-butyl carba-
zate, trypsin, streptozotocin (STZ), and fluorescein isothio-
cyanate isomer I (FITC) were obtained from Sigma-Aldrich
(St Louis, MO). An Illustra NAP-5 column was purchased from
GE Healthcare (Buckinghamshire, UK) and phosphate
buﬀered saline (PBS, pH 7.4) from Tech & Innovation (Seoul,
Korea). The Coomassie Plus (Bradford) protein assay reagent
was purchased from Thermo Scientific (Rockford, IL) and the
human EGF ELISA kit was obtained from Peprotech (Rocky
Hill, NJ). The hydroxyproline assay kit was purchased from
Abcam, Inc. (Cambridge, MA) and 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-tetrazolium bromide (MTT) was purchased
from Promega (Madison, WI). A 24-well transwell insert was
purchased from Millipore (Bedford, MA).
Polydimethylsiloxane (PDMS, Sylgard 184) was purchased
from Hana Technology (Anyang, Korea). Immortalized
human epidermal keratinocytes (HaCaT cells) were kindly
donated by Kyong-Tai Kim (POSTECH, Pohang, Korea).
Dulbecco’s modified Eagle’s medium (DMEM) was purchased
from Gibco (Grand Island, NY). Human vascular endothelial
growth factor (VEGF), rat tumor necrosis factor-α (TNF-α) and
interleukin-1 (IL-1) ELISA kits were purchased from
eBioscience (Vienna, Austria). The transforming growth
factor-β (TGF-β) ELISA kit was purchased from R&D Systems
(Minneapolis, MN). All chemicals were used without further
purification. Male SD rats weighing 230–250 g were pur-
chased from Orient (Seoul, Korea). All the procedures and
experimental protocols were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) of
Samsung Biomedical Research Institute (SBRI).
Synthesis of HA–EGF conjugates
Aldehyde-modified HA (HA–ALD) was prepared to synthesize
HA–EGF conjugates. Briefly, 0.5 g of HA with a molecular
weight (MW) of 200 kDa was dissolved in 50 mL of distilled
water. Two molar excess of sodium periodate was added to the
HA solution and stirred for 6 h in the dark. Ethylene glycol
(0.5 mL) was added to the reaction mixture and stirred for 2 h
to terminate the reaction. The resulting product was poured
into a dialysis membrane tube (MW cut oﬀ = 10 kDa) and dia-
lyzed against 0.1 M of NaCl aqueous solution and distilled
water for 3 days. The aldehyde content was analyzed by 1H
NMR (DPX500, Bruker, Germany). After that, 1 mg of EGF dis-
solved in PBS (pH 7.4) was transferred to sodium acetate
buﬀer (pH 5.5) using Illustra NAP-5 columns and mixed with
HA–ALD having an aldehyde content of 20 mol%. The HA–EGF
conjugate was synthesized by the coupling reaction between
aldehyde groups of HA–ALD and N-terminal amine groups of
EGF. The number of EGF molecules per single HA chain in the
feed was adjusted to be 10. Sodium cyanoborohydride at
5 molar excess of HA repeating unit was added for the
reduction of hydrazine bonds at room temperature for 24 h.
After conjugation, 5 molar excess of ethyl carbazate was added
with sodium cyanoborohydride and stirred for 24 h to block
the remaining aldehyde group in HA–EGF conjugates. The
resulting HA–EGF conjugate solution was purified using a cen-
trifugal filter (MW cut oﬀ = 10 kDa) to remove unreacted EGF
and other chemicals. Other HA–EGF conjugates were also syn-
thesized using HA–ALD with a MW of 10 or 100 kDa via the
same method.
Characterization of HA–EGF conjugates
The synthesized HA–EGF conjugates were analyzed by GPC
comparing the retention time before and after the conjugation
of HA with EGF. GPC was performed using the following
systems: a Waters 717 Plus autosampler, Waters 1525 binary
HPLC pump, Waters 2487 dual λ absorbance detector, and
Ultrahydrogel™ 1000 connected with an Ultrahydrogel™ 500
column. The mobile phase was PBS at pH 7.4 and the flow rate
was 0.4 mL min−1. The detection wavelength was 280 nm. The
concentration of EGF in HA–EGF conjugates was determined
by using the Bradford assay. The immunological binding
aﬃnity of EGF and HA–EGF conjugates to the anti-EGF anti-
body was assessed by human EGF ELISA. The secondary struc-
ture of HA–EGF conjugates was analyzed by CD spectroscopy.
The CD spectra of EGF and HA–EGF conjugates in PBS were
obtained using a UV spectrophotometer (JASCO J-1500, Essex,
UK) under a nitrogen atmosphere. A quartz cuvette with a path
length of 2 mm was used and data were acquired at 0.2 mm of
intervals with a response time of 1 s. The spectrum of PBS was
subtracted from each spectrum and the residual ellipticity was
calculated by averaging the results of three scans.
Enzymatic degradation of HA–EGF conjugates
HA–EGF conjugates and EGF (both 1 μg mL−1) were dissolved
in PBS, respectively. To assess protein stability against proteo-
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lytic degradation, trypsin was added to the samples and incu-
bated at 37 °C for designated times. Samples (200 μL) were
taken at predetermined times and snap-frozen in liquid nitro-
gen. At the end of the experiment, all samples were defrosted
and analyzed by human EGF ELISA.
In vitro stability test of HA–EGF conjugates
The long-term stability of EGF and HA–EGF conjugate was
evaluated by ELISA after incubation in PBS at a concentration
of 0.1 mg mL−1 and 37 °C for up to 6 months. At pre-
determined time intervals, each sample was immediately
diluted 5000 times with PBS and stored at −80 °C before
ELISA. Samples were analyzed by human EGF ELISA kits. Four
replicates were performed for the experiment.
Preparation of patch-type HA–EGF conjugates
The patch-type HA–EGF conjugates were prepared from PDMS
molds with 8 mm holes by casting HA solution containing
HA–EGF conjugates. PDMS molds were prepared by curing a
mixture of PDMS precursors and curing agents (weight ratio of
10 : 1) at 60 °C for 12 h, followed by punching the cured
PDMS sheet with an 8 mm biopsy punch. Before casting HA
patches, the molds were sterilized by UV irradiation in the
clean bench. HA solution (7 w/v%, 0.2 mL) with a MW of
200 kDa in PBS (pH 7.4) containing EGF (1 μg) or HA–EGF con-
jugates (10 μg, EGF 1 μg) was poured into the holes of PDMS
molds and then dried at 25 °C for 36 h. The prepared HA
patches (8 mm disk of 0.5 mm thickness) were sealed and
stored at 4 °C prior to use.
Characterization of patch-type HA–EGF conjugates
High resolution field-emission scanning electron microscopy
(SEM, JEOL JSM-7410F) was used to characterize the mor-
phology of patch-type HA–EGF conjugates after coating with
platinum. To observe the surface of patch-type HA–EGF conju-
gates with 10, 100, or 200 kDa MW before and after hydration,
three types of patch-type HA–EGF conjugates were hydrated for
the same time and simultaneously put into liquid nitrogen. A
layer of conductive adhesive was pasted to the dedicated SEM
object stage and the patches were attached to the stage for the
observation of the surface.
FITC labeling of EGF and HA–EGF conjugates
For in vitro release and cell-binding tests, EGF and HA–EGF
conjugates were fluorescently labeled with FITC. Twenty molar
excess of FITC was added to EGF and HA–EGF conjugate solu-
tions dissolved in sodium carbonate buﬀer (pH 9.0). The reac-
tion mixture was stirred at room temperature overnight in the
dark and purified using an Illustra NAP-5 column. The result-
ing FITC-labeled EGF (EGF–FITC) or FITC-labeled HA–EGF
(HA–EGF–FITC) conjugate solution was incorporated into HA
patches for further experiments.
In vitro release test of HA–EGF conjugates from HA patches
In vitro release profiles of HA–EGF conjugates incorporated
into HA patches were investigated by using transwell inserts.
HA patches containing HA–EGF–FITC conjugates were put
onto the upper wells. Then, the lower wells were filled with
PBS (pH 7.4) and maintained at 37 °C. At predetermined time
points, PBS was sampled from the lower wells, which were
refilled with fresh PBS. The amount of the released HA–EGF–
FITC conjugate was analyzed by measuring the intensity of
FITC fluorescence (Fluoroskan Ascent FL, Thermo Labsystem,
Beverly, MA).
Binding test of HA–EGF conjugates to HaCaT cells
HaCaT cells were seeded into the cell culture plate. After incu-
bation for 24 h, excess EGF or HA was added to the cell culture
plate for preincubation. Then, the cells were washed with PBS
three times and treated with HA–EGF–FITC conjugates. After
incubation for 2 h, the cells were washed with PBS three times
and analyzed with a confocal microscope (Fluoview FV500,
Olympus, Tokyo), flow cytometer (FACSCalibur, BD
Biosciences, San Jose, CA), and a fluorometer.
HaCaT cell proliferation assay
HaCaT cells were seeded into 96-well plates at a concentration
of 5 × 104 cells per mL in DMEM and incubated for 24 h. For
the proliferation assay, HA–EGF conjugates in serum-free
media (SFM) were added to HaCaT cells. The serially diluted
HA–EGF conjugates in SFM were incubated at 37 °C for 3 days.
After 3 days, cell proliferation was assessed by MTT. In control
groups, the added amount of EGF or HA/EGF mixture was the
same as that of HA–EGF conjugates.
Quantification of VEGF secreted from HaCaT cells
To assess the amount of VEGF secreted from HaCaT cells in
response to HA–EGF conjugates, HaCaT cells were seeded into
96-well plates at a concentration of 5 × 104 cells per mL in
DMEM and incubated for 24 h. After that, HA–EGF conjugates
in SFM were added to HaCaT cells. The serially diluted HA–
EGF conjugates in SFM were incubated at 37 °C for 3 days.
After 3 days, cell supernatants were sampled and assessed by
human VEGF ELISA. The amounts of secreted VEGF were nor-
malized by cell numbers. In control groups, the added amount
of EGF was the same as that of HA–EGF conjugates.
In vitro scratch assay using HaCaT cells
The biological activity of EGF or HA–EGF conjugates on HaCaT
cells was investigated by the scratch assay. HaCaT cells were
seeded into the cell culture plate. After the cells reached 95%
confluency, the cells were scraped in a straight line to create a
scratch with a p200 pipette tip. Then, the complete medium
was replaced with SFM containing EGF or HA–EGF conjugates
with the same concentration of EGF. The plates were incubated
at 37 °C in a humidified 5% CO2 cell culture incubator and the
migration of the cells was observed by optical microscopy for
2 days.
Paper Biomaterials Science
1022 | Biomater. Sci., 2018, 6, 1020–1030 This journal is © The Royal Society of Chemistry 2018
Pu
bl
ish
ed
 o
n 
14
 M
ar
ch
 2
01
8.
 D
ow
nl
oa
de
d 
by
 P
O
ST
EC
H
 L
ib
ra
ry
 o
n 
6/
5/
20
19
 8
:2
2:
22
 A
M
. 
View Article Online
In vivo treatment of diabetic wound model rats with HA–EGF
conjugates
Diabetes mellitus was induced in rats by intraperitoneal injec-
tion of STZ (50 mg kg−1) for 5 consecutive days. The blood
glucose level was measured with a glucometer at 4 weeks after
the first STZ injection. Rats with a blood glucose level higher
than 250 mg dL−1 were considered diabetic. A wound was
made using an 8 mm biopsy punch at the center of the dorsal
skin of each diabetic rat. The rats were randomly divided into
four groups (four rats per group) and each wound was topically
treated with HA (non-incorporated patch), EGF (EGF-incorpor-
ated patch), or HA–EGF conjugates (HA–EGF conjugate-incor-
porated patch) daily for 16 days. The dose of administered EGF
was 1 μg per patch for both EGF and HA–EGF conjugates. The
degree of wound healing on the dorsal skin was assessed by
measuring the wound area using a digital camera on days 0, 4,
8, 12, and 16. The rate of wound healing was expressed as the
percentage of the remaining wound area. The rats were sacri-
ficed 16 days post-treatment for histological analysis and cyto-
kine analysis of wounds. The harvested wound tissues were
fixed in 4% formaldehyde at room temperature overnight. The
fixed wound tissues were embedded in paraﬃn, which were
cut into serial sections, heated in a vacuum oven at 60 °C for
20 min, deparaﬃnized, and hydrated. Then, the sections were
stained with hematoxylin and eosin (H&E) and Masson’s tri-
chrome for standard evaluation and observation of collagen
formation in the wound area, respectively. Furthermore, the
homogenate of dissected wound tissues was added to the well
of an ELISA kit containing 0.1 mL of the lysis buﬀer, and the
cytokine level of the wound tissues was measured by ELISA. To
quantify the amount of collagen in the wound area, the hydro-
xyproline assay was conducted according to the manufacturer’s
instructions.
Statistical analysis
Data are expressed as mean ± standard deviation from several
separate experiments. Statistical analysis was conducted via
the unpaired t-test for the comparison of the two groups, and
the one-way analysis of variance (ANOVA) followed by
Dunnett’s multiple comparison test was performed for the
comparison of more than two groups. The values for *P < 0.05,
**P < 0.01, ***P < 0.001, and ****P < 0.0001 were considered
statistically significant.
Results and discussion
Synthesis and characterization of HA–EGF conjugates
As shown in Fig. 1, we developed an HA patch incorporating
HA–EGF conjugates for the treatment of chronic wound
healing. After topical application, the HA patch can deliver
HA–EGF conjugates in a sustained manner. HA–EGF conju-
gates can protect EGF from proteolytic degradation by steric
hindrance and shielding of HA, interact with the cells in skin
tissues such as keratinocytes and fibroblasts via receptors of
HA and EGF, and stimulate various cell functions for skin
tissue regeneration.
We developed three types of HA–EGF conjugates with a MW
of 10, 100, or 200 kDa before selecting a suitable HA–EGF con-
jugate for chronic wound healing. Aldehyde groups were intro-
Fig. 1 Schematic illustration of a ﬁlm type HA patch incorporating HA–EGF conjugates for chronic wound healing.
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duced into HA molecules by treatment with sodium periodate.
Then, EGF molecules were evenly grafted to the aldehyde
groups on the long chain of HA by reductive amination. As pre-
viously reported elsewhere,17 during the reaction, aldehyde
groups can preferably react with N-terminal primary amine
groups of EGF rather than ε-amino groups of lysine at a low
pH around 5.5 due to the pKa diﬀerence between N-terminal
primary amines and lysine amines in EGF. The selective conju-
gation on N-terminal amine groups can contribute to the
maintenance of the secondary structure and biological activity
of EGF after conjugation.17 The successful synthesis of HA–
EGF conjugates was confirmed by GPC. As shown in Fig. 2a,
the peaks of the three types of conjugates appeared at a
shorter retention time than that of EGF. In addition, HA–EGF
conjugates with the higher MW of HA showed the shorter
retention time. According to the peak area of unreacted EGF
before purification, the conjugation eﬃciency was calculated
to be higher than 70%.
The CD analysis revealed that the secondary structure of
EGF in HA–EGF conjugates remained stable without signifi-
cant denaturation, showing a deep negative peak of EGF in the
wavelength range of 200–205 nm (Fig. 2b). The immunological
bioactivity of HA–EGF conjugates by human EGF ELISA and
Bradford assay was comparable to that of native EGF without
conjugation (Fig. 2c), likely due to the selective conjugation
onto N-terminal amine groups. We also showed that the
exposure of EGF to trypsin led to a reduction in EGF activity by
ELISA (Fig. 2d). In contrast, HA–EGF conjugates showed high
bioactivity even after treatment with trypsin, confirming the
shielding eﬀect of HA from proteolytic degradation.
Furthermore, enzymatic stability of HA–EGF conjugates
increased with the increasing MW of HA. The enzymatic stabi-
lity to proteolysis is one of the key factors for in vivo improved
bioactivity of polymer-conjugated proteins.6,8,11,13
Preparation and characterization of HA patch incorporating
HA–EGF conjugates
A recent study showed that the conjugation of the antibody to
high MW HA resulted in slow diﬀusion by six times in the
wound bed compared with that of the unconjugated anti-
body.18 In the same manner, HA–EGF conjugates may diﬀuse
more slowly than EGF in the wound area. We prepared a film
type HA patch incorporating HA–EGF conjugates for more
stable and sustained delivery, and convenient operation in
vivo. The HA patch containing EGF or HA–EGF conjugates for
wound healing was prepared by the solvent casting of HA and
EGF or HA–EGF conjugate solutions after filling the mixtures
into the holes of PDMS molds (Fig. 3a). The patch containing
HA–EGF conjugates became a viscous liquid on the wet wound
tissue and delivered HA–EGF conjugates in a sustained
manner by infiltrating into the wound tissue.
As shown in Fig. 3b, the in vitro release profile of HA–
EGF conjugates incorporated into the HA patch depending
on the MW of HA in the patch matrix. The higher MW of the
HA patch showed the slower release of HA–EGF conjugates
from the patch. The result might be attributed to the pore
Fig. 2 (a) GPC analysis of EGF and HA–EGF conjugates. (b) CD spectra of EGF and HA–EGF conjugates. (c) The ratios of EGF concentrations in HA–
EGF conjugates determined by ELISA and Bradford assay (n = 3). (d) The proteolytic degradation of EGF and HA–EGF conjugates 3 h after treatment
with trypsin. The trypsin-untreated group is represented as 100% (n = 3).
Paper Biomaterials Science
1024 | Biomater. Sci., 2018, 6, 1020–1030 This journal is © The Royal Society of Chemistry 2018
Pu
bl
ish
ed
 o
n 
14
 M
ar
ch
 2
01
8.
 D
ow
nl
oa
de
d 
by
 P
O
ST
EC
H
 L
ib
ra
ry
 o
n 
6/
5/
20
19
 8
:2
2:
22
 A
M
. 
View Article Online
size produced within the HA patch during hydration
(Fig. 3c). Before hydration, there was no pore on the surface
of the HA patch. After hydration, pores were formed on the
surface of the HA patch with the following sizes: 20, 5, and
1 μm in 10, 100, and 200 kDa HA patches, respectively.
Since a higher MW HA patch appeared to have smaller
pores, incorporated HA–EGF conjugates were likely to be
released more slowly.
Fig. 3 (a) Photographic image of the HA patch incorporating HA–EGF conjugates (scale bar = 5 mm). (b) In vitro release proﬁles of the HA–EGF
conjugate from HA patches (n = 4). (c) SEM images of the surface of the HA patch before (top row, scale bar = 1 μm) and after (bottom row, scale
bar = 100 μm) hydration. (d) The proteolytic degradation of EGF, HA/EGF mixture, and HA–EGF conjugate by trypsin. The trypsin-untreated group is
represented as 100% (n = 3). (e) The stability of EGF and HA–EGF conjugates in PBS (pH 7.4) (n = 3).
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Fig. 4 Eﬀect of 200 kDa HA–EGF conjugate on HaCaT cells. (a) Confocal microscopy images and ﬂow cytometric analysis for the binding of the
HA–EGF conjugate to the cells after HA or EGF preincubation (n = 3). (b) Quantiﬁcation of the ﬂuorescence in (a). The non-treated cell group is rep-
resented as 100% (n = 3). (c) The eﬀect of the HA–EGF conjugate on the cell proliferation with increasing concentration of EGF in serum-free
medium. The cultured cell group in complete cell culture medium is represented as 100% (n = 3). (d) The eﬀect of the HA–EGF conjugate on the
VEGF secretion from the cells treated with HA–EGF conjugate or EGF in serum-free medium. The cultured cell group in complete cell culture
medium is represented as 100% (n = 3). (e) Optical microscopy images for cell migration after adding EGF, HA/EGF mixture, or HA–EGF conjugate.
The red lines represent the boundary between empty region and cells.
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To investigate the eﬀect of HA conjugation on EGF stability,
we incubated native EGF and HA–EGF conjugates in trypsin
(Fig. 3d) and PBS (pH 7.4) solutions (Fig. 3e) for a specified
time period. HA–EGF conjugates exhibited superior stability to
native EGF, indicating that the conjugation of EGF with a long-
chain HA polymer contributed to the protection of the EGF
molecule. In addition, the patch-type delivery vehicle in wound
healing might protect EGF from degradation and enable a sus-
tained release of suﬃcient concentrations of active HA–EGF
conjugates, resulting in the long-term retention of EGF in the
epidermis and dermis.
Eﬀect of HA–EGF conjugates on HaCaT cells
The proliferation and migration of keratinocytes at the wound
margin area might contribute to the re-epithelialization
process for wound repair. Accordingly, we investigated the
eﬀect of the HA–EGF conjugate on the re-epithelialization
using HaCaT cells as model keratinocytes. The binding behav-
ior of the HA–EGF conjugate onto HaCaT cells was firstly
studied using fluorescence-based methods such as confocal
microscopy, flow cytometry, and microplate fluorometric assay.
As shown in Fig. 4a and b, the HA–EGF conjugate appeared to
bind onto HaCaT cells through both HA–CD44 and EGF–EGFR
interactions, reflecting the higher binding aﬃnity of the HA–
EGF conjugate than native EGF to HaCaT cells. We further
assessed the proliferation and VEGF secretion of HaCaT cells
in response to the HA–EGF conjugate. The viability of HaCaT
cells treated with the HA–EGF conjugate was higher than that
with EGF or HA/EGF mixture at various concentrations of EGF
(Fig. 4c). In addition, the amount of VEGF secreted from
HaCaT cells in response to the HA–EGF conjugate was also
higher than native EGF, indicating that the HA–EGF conjugate
might influence the angiogenic process by signaling keratino-
cytes in the wound bed (Fig. 4d).
The wound closure by the migration of keratinocytes from
the surrounding epidermis might also be of pivotal impor-
tance. The scratch wound assay revealed that HaCaT cell
migration was enhanced in response to the HA–EGF conjugate
compared with native EGF (Fig. 4e). As previously reported
elsewhere, HA can actively participate in keratinocyte
migration and proliferation through interactions with the HA
receptors of CD44 and RHAMM.19 From this point of view, the
HA/EGF mixture might induce a higher migration and prolifer-
ation eﬀect than native EGF through the synergistic eﬀect of
HA and EGF. Remarkably, the migratory and proliferative
capacities of the HA–EGF conjugate were superior to those of
the HA/EGF mixture. The result might be explained by the
multivalent binding aﬃnity of the HA–EGF conjugate on
HaCaT cells via the synergistic eﬀect of HA and EGF.20,21 In a
similar study, multivalent conjugation of the growth factor
Sonic hedgehog (Shh) to HA yielded enhanced Shh-pathway
activation, inducing the angiogenic function compared with
that by the equivalent dose of unconjugated Shh.22–24
Although the underlying signaling mechanism caused by the
HA–EGF conjugate requires further investigation, the HA–EGF
conjugate can certainly increase keratinocyte proliferation,
VEGF secretion, and migration, likely contributing to the fast
re-epithelialization during wound repair.
In vivo assessment of HA–EGF conjugate incorporated into the
HA patch
Diabetes was induced into rats by intraperitoneal daily injec-
tion (50 mg kg−1) of STZ for 5 days. The blood glucose level
was measured at 4 weeks after the first STZ injection using a
glucometer. Rats with a blood glucose level higher than
250 mg dL−1 were considered diabetic. The chronic wound
model was induced using an 8 mm biopsy punch at the center
of the dorsal skin of each diabetic rat and the wound healing
Fig. 5 (a) Photographic images of wound areas for 16 days and (b) changes in the measured area after treatment of 200 kDa HA patches with incor-
porated EGF or 200 kDa HA–EGF conjugate (n = 4). **P < 0.01 and ***P < 0.001 versus EGF-treated group.
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process was evaluated after treatment with HA–EGF conjugates
incorporated into the HA patch. After wound formation, the
wound area is hydrated within 5–10 min by the wound fluid
eﬀused from the scar. The HA patch appeared to be swollen
and slowly dissolved into the viscous liquid. The dissolved HA
patch could be steadily attached to the wound area. As shown
in Fig. 3b, the HA–EGF conjugate might diﬀuse from the
viscous gel-like solution. To measure the wound size, the
wound area was photographed every 4 days (Fig. 5a). The
wound area measured each day was normalized by considering
the initial wound area as 100% (Fig. 5b). The half healing time
(HT50), which is the time required for the reduction of the
wound area to half of its initial size, was calculated by extra-
polating from the measured data. Although the wound size
decreased by natural healing for the untreated control group,
the wound closure was accelerated for groups treated with EGF
and HA–EGF conjugate incorporated into the HA patch. The
HT50 for the HA–EGF conjugate was only 5.8 days, which was
much lower than 9.5 days for the EGF group, reflecting the
healing eﬀect of HA–EGF conjugates on the skin wound.
Histological analysis with H&E staining and Masson’s tri-
chrome staining was performed for further therapeutic ana-
lysis (Fig. 6). On the punched skin tissues, damaged skin
tissues showed loosely arranged and less granulated tissue
structures. However, after treatment with the HA–EGF conju-
gate incorporated into the HA patch, the damaged area was
Fig. 6 Histological analysis with H&E staining and Masson’s trichrome staining 16 days after treatment with 200 kDa HA patch with incorporated
EGF or 200 kDa HA–EGF conjugate on diabetic wound model tissues (scale bar = 500 μm).
Fig. 7 Cytokine analysis of (a) TNF-α, (b) IL-1 and (c) TGF-β and hydroxyproline assay of (d) collagen content in the homogenate of the dissected
wound tissues 16 days after treatment with 200 kDa HA patches with incorporated EGF or 200 kDa HA–EGF conjugate on diabetic wound model
(n = 4).
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significantly reduced and the border between damaged and
normal tissues was ambiguous compared with other groups.
In addition, the recovered skin tissues showed almost com-
plete re-epithelialization and granulation of dermal tissues.
Particularly, the HA–EGF conjugate-treated group showed a
mostly recovered hypodermis structure with white granular
tissues, which might be attributed to the biological interaction
of HA–EGF conjugates with skin cells and the prolonged resi-
dence of the HA–EGF conjugate. In consistent with the results
of H&E staining, Masson’s trichrome staining also showed the
positive eﬀect of the HA–EGF conjugate on skin wound
healing. The remarkable collagen deposition in the dermis of
the regenerated skin was observed at day 16 with the strongest
blue staining intensity for the regenerated collagens.
The cytokine analysis in skin tissues also supported the
therapeutic eﬀect of the HA–EGF conjugate incorporated into
the HA patch (Fig. 7a–c). The HA–EGF conjugate reduced the
high level of inflammatory cytokines such as TNF-α and
IL-1 more eﬀectively than other groups including the EGF-
treated group. The HA–EGF conjugate incorporated into the
HA patch also significantly elevated the level of TGF-β known
to stimulate cellular proliferation. The collagen content in
wound tissues was also drastically enhanced after treatment
with the HA–EGF conjugate at day 16, as shown in Fig. 7d. All
these results revealed the therapeutic eﬀect of the patch-type
HA–EGF conjugates on skin wound healing by the prolonged
residence of EGF in wound tissues, the long-term release of
the conjugate from the HA patch, and the improved interaction
with skin cells. Similarly, recent other studies have demon-
strated that HA conjugation could increase the activity of
proteins.18,22–27 The cytokine neutralizing HA–antibody conju-
gates appeared to strengthen the binding aﬃnity for inflam-
mation mediators with the simultaneous activation of CD44/
RHAMM and the suppression of cytokine-signaling net-
works.25 The used HA with a MW of 100–300 kDa was also
reported to promote wound healing.28 In addition, as pre-
viously reported elsewhere,14,29 the HA–EGF conjugate might
be delivered eﬃciently into deep skin tissues. Taken together,
the HA–EGF conjugate might be successfully developed for the
treatment of chronic wounds with advantages such as facilitat-
ing topical delivery and interaction with dual receptors, and
alleviating the degradation of EGF in diabetic chronic wounds.
Conclusions
We developed a HA–EGF conjugate incorporated into a HA
patch for diabetic wound healing. HA–EGF conjugates were
synthesized by conjugating the amine group of EGF to alde-
hyde-modified HA by reductive amination. After in vitro charac-
terization for improved enzymatic stability and biological
activity of HA–EGF conjugates on skin cells, we incorporated
HA–EGF conjugates into the HA patch by a simple drying
method at room temperature for sustained long-term delivery
to the skin wound. The HA–EGF conjugate incorporated into
the HA patch showed a more significant in vivo wound healing
eﬀect than the other control samples including EGF. The con-
jugation of HA with EGF appeared to protect EGF against
enzyme degradation and enhance proliferation, VEGF
secretion, and migration of human keratinocytes through both
HA–CD44 and EGF–EGFR interactions. From all these results,
we could confirm the feasibility of the HA–EGF conjugate
patch for diabetic wound healing applications.
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